In its healthcare conference, Shire slashed its 2020 sales forecast from $20bn (given two years back) to $17-18bn and also pushed out the strategic review of the neuroscience (ADHD) business to H2 18. Until the final decision on the review, it will be restructuring the group into two businesses – rare diseases (accounting for 70% of the group sales) and neuroscience. Post the review, Shire will decide whether to keep the businesses under one roof or go for other options such as a separa
09 Jan 2018
2020 target cut; ADHD review to take longer
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2020 target cut; ADHD review to take longer
Shires Income PLC GBP (SHRS:LON) | 226 0 0.0% | Mkt Cap: 93.7m
- Published:
09 Jan 2018 -
Author:
Kamla Singh -
Pages:
2
In its healthcare conference, Shire slashed its 2020 sales forecast from $20bn (given two years back) to $17-18bn and also pushed out the strategic review of the neuroscience (ADHD) business to H2 18. Until the final decision on the review, it will be restructuring the group into two businesses – rare diseases (accounting for 70% of the group sales) and neuroscience. Post the review, Shire will decide whether to keep the businesses under one roof or go for other options such as a separa